Delhi HC requires Sun Pharma to seek clearance before semaglutide launch
The Delhi High Court has directed Sun Pharma to obtain court permission before launching oral semaglutide amid Novo Nordisk’s patent suit, potentially delaying its entry into India’s fast-growing weight-loss and diabetes-drug market.
The development
Delhi High Court ordered Sun Pharma to seek approval before launching oral semaglutide amid Novo Nordisk’s patent suit. The ruling affects India’s fast-growing generic weight-loss and diabetes-drug market, where Sun is the second-largest semaglutide player.
The numbers
- ₹46 crore generic semaglutide injectable sales in July
- ₹27 crore Novo Nordisk injectable sales in July
- ₹20 crore Novo Nordisk oral semaglutide sales
- ₹11 crore generic oral semaglutide tablet sales
Why it matters to operators and investors
The patent dispute underscores the value of licensing, settlement, or alternative GLP-1 partnership options to secure market access while litigation remains unresolved.
The counter-case
The order may be a procedural safeguard rather than a substantive bar on Sun Pharma’s launch. If the relevant Novo Nordisk patent claims are narrow, vulnerable to invalidity challenges, near expiry, or do not cover Sun’s formulation/process, the commercial delay could be limited. India’s obesity-drug market is also still nascent and price-sensitive, so even a successful generic launch may not immediately translate into material revenue or share gains.